Calliditas: Feedback from Travere’s Q4 results - Redeye

Travere reported its Q4 result after the market close on 15 February. Travere reported a Q4 patient enrollment 459 in an earlier trading update, including Q4 FILSPARI sales of USD 40m. The patient enrollment seems to have stalled after the inconclusive 2-year results reported in late September. Travere is more upbeat regarding the sales conversation than patient enrollment growth, including the first six weeks of 2024. The company expects to file for full approval and is hopeful to avoid an FDA ADCOM meeting and secure a six-month priority review.

Länk till analysen i sin helhet: https://www.redeye.se/research/980963/calliditas-feedback-from-traveres-q4-results?utm_source=finwire&utm_medium=RSS